Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone versus placebo for fibrotic hypersensitivity pneumonitis
ISRCTN58111563Phase 3Recruiting
- Sponsor
- University of Exeter
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Fibrosing hypersensitivity pneumonitis (fHP) comparing Prednisolone with Placebo (2 arms). Primary endpoint: Primary: change in absolute forced vital capacity at 26 weeks. Started May 2025; status: recruiting.
02
Drugs
prednisolone
03
Conditions
Fibrosing hypersensitivity pneumonitis (fHP)
Beyond the preview
Go deeper on ISRCTN58111563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN58111563.